Loading…
Employees: 246
Size Arvinas (ARVN) is a United States Health Care company (Biotechnology) with a market value of $420M, the 2821st largest of 3,117 United States companies the cockpit tracks. Shares closed at $6.41 on 6 Nov 2026.
Performance Over six months the shares fell 36.6%, against -18.4% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 11.8% over the last twelve months (peer median +13.3%); the operating margin is -10.1% (peer median -0.1%).
Backlog Backlog (remaining performance obligations) was $190M at 31 Mar 2026, down 27% on a year earlier — 2.1 years of trailing revenue. Backlog detail →
Short interest Short interest is 8.6% of the free float (15 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $275M | $263M | $263M | $78.5M | $131M |
| Revenue growth | — | 0% | +236% | -40% | — |
| Gross profit | $262M | $257M | $257M | $71.8M | $123M |
| EBITDA | -$23.2M | -$110M | -$200M | -$395M | -$255M |
| Net income | -$9.50M | -$80.8M | -$199M | -$367M | -$282M |
| Free cash flow | -$160M | -$276M | -$261M | -$351M | -$280M |
| Capital expenditure | $1.50M | $1.90M | $1.80M | $2.90M | $6.80M |
| Total debt | $7.60M | $9.10M | $9.90M | $3.40M | $5.50M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ARVN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.7% | -9.6% | 7th lowest of 21 |
| 6-month return | -36.6% | -18.4% | 3rd lowest of 20 |
| Distance from 52-week high | -55.8% | -42.6% | 6th lowest of 21 |
| Revenue growth (TTM) | -11.8% | +13.3% | 3rd lowest of 18 |
| Operating margin | -10.1% | -0.1% | 8th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 1.8× | 4.1% | +6.5% |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 2.5× | -20.2% | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | 0.7× | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 4.2× | 53.3% | +37.6% |
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | 10.7× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | 6.4× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 12.7× | 5.8% | +70.5% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | 5.9× | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | 12.1× | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 2.3× | 18.2% | +7.3% |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
Arvinas reported $190M of remaining performance obligations at 31 Mar 2026, down 27% from a year earlier and down 8% from the previous quarter. That is 2.1 years of trailing revenue already under contract. Book-to-bill last quarter: 0.00.